10-May-2024
Piper Sandler Keeps Their Buy Rating on Omnicell (OMCL)
TipRanks (Wed, 8-May 7:11 AM ET)
Omnicell Supports Global Charity Mercy Ships with Pharmacy Technology Donation
Business Wire (Mon, 6-May 4:23 PM ET)
Omnicell to Present at the BofA Securities 2024 Health Care Conference
Business Wire (Fri, 3-May 4:01 PM ET)
Omnicell Announces First Quarter 2024 Results
Business Wire (Thu, 2-May 7:30 AM ET)
Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer
Globe Newswire (Mon, 22-Apr 4:05 PM ET)
Business Wire (Tue, 16-Apr 4:01 PM ET)
Omnicell to Release First Quarter 2024 Financial Results on May 2, 2024
Business Wire (Mon, 8-Apr 4:01 PM ET)
Omnicell to Present at the virtual KeyBanc Annual Life Sciences & MedTech Investor Forum
Business Wire (Mon, 11-Mar 5:11 PM ET)
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
Omnicell trades on the NASDAQ stock market under the symbol OMCL.
As of May 10, 2024, OMCL stock price declined to $30.12 with 514,317 million shares trading.
OMCL has a beta of 0.61, meaning it tends to be less sensitive to market movements. OMCL has a correlation of 0.03 to the broad based SPY ETF.
OMCL has a market cap of $1.38 billion. This is considered a Small Cap stock.
Last quarter Omnicell reported $246 million in Revenue and $.03 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.12.
In the last 3 years, OMCL stock traded as high as $187.29 and as low as $25.69.
The top ETF exchange traded funds that OMCL belongs to (by Net Assets): IJR, CALF, VTI, VB, IWM.
OMCL stock has underperformed the market in the last year with a return of -55.1%, while SPY returned +27.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in OMCL shares. However, OMCL has outperformed the market in the last 3 month and 2 week periods, returning +9.9% and +8.1%, while SPY returned +4.2% and +2.5%, respectively. This indicates OMCL has been having a stronger performance recently.
OMCL support price is $29.52 and resistance is $30.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMCL stock will trade within this expected range on the day.